ACON · Aclarion, Inc.

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock.

100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan).

The Reporting Person purchased common stock on the public market on May 12, 2026.

The Reporting Person purchased common stock on the public market on May 11, 2026.

The Reporting Person purchased common stock on the public market on 5/6/2026.

The Reporting Person purchased common stock on the public market on 11/26/2025.

The option will vest 25% on September 2, 2026. The remaining 75% will vest thereafter in 36 equal monthly installments over the following three years.

On February 16, 2023, the Company sold one (1) share of the Company's newly designated Series A Preferred Stock to the reporting person in a private placement for an aggregate purchase price of $1,000. The Series A Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series A Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Share of Series A Preferred Stock will not be entitled to receive dividends of any kind.

The holder of the Share of Series A Preferred Stock will not be entitled to receive dividends of any kind. The one share of Series A Preferred Stock will have 15,000,000 votes and will vote together with the outstanding shares of the Company's common stock as a single class exclusively with respect to any proposal to amend the Company's Certificate of Incorporation to effect a reverse stock split of the Company's common stock. The Share of Series A Preferred Stock will be voted, on any such reverse stock split proposal in the same proportion as shares of common stock are voted on such proposal (excluding any common shares that are not voted). The Series A Preferred Stock otherwise has no voting rights, except as may otherwise be required by Delaware Law.

The outstanding share of Series A Preferred Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split. Upon such redemption, the holder of the Series A Preferred Stock will receive consideration of $1,000.00 in cash. On March 28, 2023, the Company redeemed the one Series A Preferred share for the $1,000 redemption price.

On February 16, 2023, the Company sold one (1) share of the Company's newly designated Series A Preferred Stock to the reporting person in a private placement for an aggregate purchase price of $1,000. The Series A Preferred Stock is not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series A Preferred Stock has no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Share of Series A Preferred Stock will not be entitled to receive dividends of any kind.

The holder of the Share of Series A Preferred Stock will not be entitled to receive dividends of any kind. The one share of Series A Preferred Stock will have 15,000,000 votes and will vote together with the outstanding shares of the Company's common stock as a single class exclusively with respect to any proposal to amend the Company's Certificate of Incorporation to effect a reverse stock split of the Company's common stock. The Share of Series A Preferred Stock will be voted, on any such reverse stock split proposal in the same proportion as shares of common stock are voted on such proposal (excluding any common shares that are not voted). The Series A Preferred Stock otherwise has no voting rights, except as may otherwise be required by Delaware Law.

The outstanding share of Series A Preferred Stock shall be redeemed in whole, but not in part, at any time (i) if such redemption is ordered by the Board of Directors in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing a reverse stock split. Upon such redemption, the holder of the Series A Preferred Stock will receive consideration of $1,000.00 in cash.

The Reporting Person purchased common stock on the public market on 12/28/2022 and 12/29/2022.

The Reporting Person purchased common stock on the public market on 12/29/2022.

The Reporting Person purchased common stock on the public market on 12/28/2022 and 12/29/2022.

This option vests in equal monthly increments over the 36 month period beginning April 22, 2022.

The Reporting Person purchased common stock on the public market on 12/29/2022.

The Reporting Person purchased common stock on the public market on 12/28/2022 and 12/29/2022.

On December 5, 2022, SC Capital 1 LLC ("SC Capital") effected a pro rata distribution of the Issuer's common stock held by SC Capital to each of the members of SC Capital.

Michael W. Dirks serves as the manager for SC Capital and may be deemed to have voting and investment power over any shares held by SC Capital. Mr. Dirks disclaims beneficial ownership of any such shares except to the extent of his pecuniary interests therein, and this report shall not be deemed an admission that Mr. Dirks is the beneficial owner of any securities held by SC Capital for purposes of Section 16 or for any other purpose.

Shares were acquired pursuant to a pro rata distribution from SC Capital 1 LLC, of which the reporting person is a non-managing member.

On December 6, 2022, the reporting person filed a Form 4 which, due to a scrivener's error, included the incorrect code "D" instead of the proper code "A" to indicate that the reporting person acquired shares. This amendment corrects that error.

The shares underlying this option grant will vest in 48 equal monthly installments succeeding the vesting commencement date of September 1, 2021.

In accordance with the reporting person's employment agreement, on September 27, 2021 the reporting person was previously granted 341,365 options with substantially identical terms to the newly granted options reported herein. The options reported herein were granted in order to satisfy the equity grant target set forth in the reporting person's employment agreement.

The shares underlying this option grant will vest in 48 equal monthly installments succeeding the vesting commencement date of October 1, 2021.

In accordance with the reporting person's employment agreement, on September 27, 2021 the reporting person was previously granted 66,934 options with substantially identical terms to the newly granted options reported herein. The options reported herein were granted in order to satisfy the equity grant target set forth in the reporting person's employment agreement.

The shares underlying this option are fully vested.

In accordance with the reporting person's employment agreement, on September 27, 2021 the reporting person was previously granted 1,204,819 options with substantially identical terms to the newly granted options reported herein. The options reported herein were granted in order to satisfy the equity grant target set forth in the reporting person's employment agreement.

This option vests in equal monthly increments over the 36 month period beginning April 22, 2022.

This option vests in equal monthly increments over the 36 month period beginning April 22, 2022.

The Reporting Person purchased common stock and warrants for common stock on the public market on 4/22/2022, which was the first day of trading after the Company's initial public offering ("IPO"). Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

This option vests in equal monthly increments over the 36 month period beginning April 22, 2022.

The Reporting Person purchased common stock and warrants for common stock on the public market on 4/22/2022, which was the first day of trading after the Company's initial public offering ("IPO"). Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

In connection with the Aclarion, Inc. initial public offering ("IPO"), 1,000 units were purchased on 4/21/2022 at the public offering price of $4.35 per unit. Each unit consisted of one share of common stock and one common stock warrant. Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

In connection with the Aclarion, Inc. initial public offering ("IPO"), 1,000 units were purchased on 4/21/2022 at the public offering price of $4.35 per unit. Each unit consisted of one share of common stock and one common stock warrant. Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

In connection with the Aclarion, Inc. initial public offering ("IPO"), 34,400 units were purchased on 4/21/2022 at the public offering price of $4.35 per unit. Each unit consisted of one share of common stock and one common stock warrant. Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

In connection with the Aclarion, Inc. initial public offering ("IPO"), 11,000 units were purchased on 4/21/2022 at the public offering price of $4.35 per unit. Each unit consisted of one share of common stock and one common stock warrant. Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

In connection with the Aclarion, Inc. initial public offering ("IPO"), 34,400 units were purchased on 4/21/2022 at the public offering price of $4.35 per unit. Each unit consisted of one share of common stock and one common stock warrant. Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.

In connection with the Aclarion, Inc. initial public offering ("IPO"), 11,000 units were purchased on 4/21/2022 at the public offering price of $4.35 per unit. Each unit consisted of one share of common stock and one common stock warrant. Each common stock warrant has an exercise price of $4.35 per common share, and may be exercised at any time up to five years from the date of issue.